Framework for rational donor selection in fecal microbiota transplant clinical trials
نویسندگان
چکیده
منابع مشابه
Designing fecal microbiota transplant trials that account for differences in donor stool efficacy.
Fecal microbiota transplantation is a highly effective intervention for patients suffering from recurrent Clostridium difficile, a common hospital-acquired infection. Fecal microbiota transplantation's success as a therapy for C. difficile has inspired interest in performing clinical trials that experiment with fecal microbiota transplantation as a therapy for other conditions like inflammatory...
متن کاملminimum requirements for reporting fecal microbiota transplant trial
fecal microbiota transplant (fmt) research trials are growing in diverse intestinal and extraintestinal conditions that are thought to be either caused or correlated with gut microbiota dysbiosis. although, the mechanism by which the microbiota results in disease initiation or progression is not fully understood, it is speculated that restoring the symbiosis by fmt could have therapeutic benefits.
متن کاملFecal Microbiota Transplant: Benefits and Risks
We commend the authors of “Weight Gain After Fecal Microbiota Transplantation” for describing this case of obesity after a fecal microbiota transplant (FMT). Fecal microbiota transplant is a highly effective therapy for recurrent Clostridium difficile infection (r-CDI), and the authors discuss possible unintended consequences in a patient after successful FMT, which could be due to alteration o...
متن کاملMicroscopic Colitis After Fecal Microbiota Transplant
Microscopic colitis (MC) is an inflammatory condition of the large bowel that is associated with chronic, nonbloody diarrhea. Colonoscopy usually demonstrates normal mucosa, while tissue biopsy reveals intraepithelial lymphocytes or a subepithelial collagen band. Although no specific antibody has been discovered, MC is associated with several autoimmune disorders such as celiac disease, Hashimo...
متن کاملClostridium difficile Infection and Fecal Microbiota Transplant.
Clostridium difficile infection (CDI) is a major source of morbidity and mortality for hospitalized patients. Although most patients have a clinical response to existing antimicrobial therapies, recurrent infection develops in up to 30% of patients. Fecal microbiota transplant is a novel approach to this complex problem, with an efficacy rate of nearly 90% in the setting of multiple recurrent C...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: PLOS ONE
سال: 2019
ISSN: 1932-6203
DOI: 10.1371/journal.pone.0222881